Last reviewed · How we verify
NCT03459144
Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen
NA trial testing verteporfin in Polypoidal Choroidal Vasculopathy in 60 participants. Completed in 30 July 2015.
30 July 2015
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 December 2012 |
| Primary completion | 30 July 2015 |
| Estimated completion | 30 July 2015 |
| Sites | 1 location across China |
Drugs / interventions tested
- verteporfin (VERTEPORFIN) — full drug profile →
- verteporfin and ranibizumab — full drug profile →
Conditions studied
- Polypoidal Choroidal Vasculopathy — all drugs for Polypoidal Choroidal Vasculopathy →
Sponsor
Sun Yat-sen University
Who can join
Adults 40 to 99, any sex, with Polypoidal Choroidal Vasculopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to compare the outcomes of different treatment methods including photodynamic therapy (PDT), intravitreal ranibizumab injection (IVR) and combination therapy under the "1+PRN" treatment regimen for polypoidal choroidal vasculopathy (PCV) and find the optimal treatment for PCV.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.
Lees JS, Dobbin SJH, Elyan BMP, Gilmour DF, et al · · 2023 · cited 12× · PMID 36318455 · DOI 10.1093/ndt/gfac305 -
Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
Lai K, Li Y, Zhou L, Zhong X, et al · · 2018 · cited 8× · PMID 29925341 · DOI 10.1186/s12886-018-0801-7
Verify or expand the search:
- PubMed search for NCT03459144
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03459144 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 8 March 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03459144.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing